RecruitingPhase 3NCT04168099
Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
Comparative Study Between the Efficacy of Oral Gemifloxacin and Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
Sponsor
Tanta University
Enrollment
60 participants
Start Date
Dec 1, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
oral Gemifloxacin versus intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Cefotaxime and a drug called Gemifloxacin for people with spontaneous bacterial peritonitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCefotaxime
Cefotaxime IV
DRUGGemifloxacin
Gemifloxacin oral
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04168099